NCT06285019 2024-02-29
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Unknown
Clinical Trials
10 trialsNCT05173298 2024-02-07
HCC
CHA University
Unknown
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05616390 2023-03-21
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05760599 2023-03-08
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
Phase 2 Unknown
NCT05396937 2022-05-31
Efficacy and Safety of T+A+RAD in HCC
Fudan University
Phase 2 Unknown
NCT05363722 2022-05-06
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT04741165 2021-02-05
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT04627363 2020-11-13
HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
Sun Yat-sen University
Phase 2 Unknown
NCT00162669 2006-09-08
Bevacizumab in Advanced Hepatocellular Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown